Evidence map›Paper›PMID 36835211›Full record

ArticleInternational journal of molecular sciences2023

Knockout of Purinergic P2Y

Kazuhiro Nishiyama, Kohei Ariyoshi, Akiyuki Nishimura, Yuri Kato, Xinya Mi, Hitoshi Kurose, Sang Geon Kim, Motohiro Nishida

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Purinergic Signalling in Physiology and Pathophysiology.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Kazuhiro NishiyamaGraduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.ORCID 0000-0002-6263-3562
Kohei AriyoshiGraduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Akiyuki NishimuraNational Institute for Physiological Sciences (NIPS), National Institutes of Natural Sciences, Okazaki 444-8787, Japan.ORCID 0000-0003-2309-3994
Yuri KatoGraduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.ORCID 0000-0002-9426-911X
Xinya MiGraduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Hitoshi KuroseGraduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Sang Geon KimCollege of Pharmacy, Dongguk University-Seoul, Goyang-si 10326, Gyeonggi-Do, Republic of Korea.
Motohiro NishidaGraduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.ORCID 0000-0002-2587-5458
Kyushu University · JPDongguk University · KRNational Institutes of Natural Sciences · JP

Funding

Japan Science and Technology Agency 21H05269Japan Science and Technology Agency 22H02772Japan Science and Technology Agency 22H04814Japan Science and Technology Agency 22K06630Japan Science and Technology Agency JPMJCR2024National Research Foundation of Korea 2017K1A1A2004511
6 · The paper itself

Abstract

Nonalcoholic steatohepatitis (NASH) is a disease that progresses from nonalcoholic fatty liver (NAFL) and which is characterized by inflammation and fibrosis. The purinergic P2Y

Indexed as

Non-alcoholic Fatty Liver DiseaseReceptors, Purinergic P2AnimalsDiet, High-FatDisease Models, AnimalHumansMiceMice, Inbred C57BLMice, KnockoutRNA, Messengerpurinoceptor P2Y6Receptors, Purinergic P2RNA, Messengerinflammationnonalcoholic steatohepatitispurinergic P2Y6 receptor

Identifiers

PMID36835211
PMCPMC9963899
OpenAlexW4320729269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.